Conexeu Sciences Inc is an early-stage medical technology company... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TMED | 33.89 | 0.71 | +2.13% |
| T. Rowe Price Health Care ETF (TMED) | |||
| JPIN | 73.91 | 0.91 | +1.25% |
| JPMorgan Diversified Return International Equity ETF (JPIN) | |||
| KURE | 17.90 | 0.16 | +0.90% |
| KraneShares MSCI All China Health Care Index ETF (KURE) | |||
| VTEI | 96.79 | 0.74 | +0.77% |
| Vanguard Intermediate-Term Tax-Exempt Bond ETF (VTEI) | |||
| CPHY | 50.73 | 0.23 | +0.46% |
| F/m Compoundr High Yield Bond ETF (CPHY) | |||
Industry Biotechnology
The Aroon Indicator for CNXU entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 14 similar instances where the Aroon Indicator formed such a pattern. In 14 of the 14 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 3 of 4 cases where CNXU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on CNXU as a result. In 4 of 6 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for CNXU just turned positive on September 17, 2026. Looking at past instances where CNXU's MACD turned positive, the stock continued to rise in 1 of 1 cases over the following month. The odds of a continued upward trend are 90%.
Following a +19.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNXU advanced for three days, in 10 of 14 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.182) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CNXU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNXU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.